Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.

Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.

Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.

Abstract: An object of the invention is to provide a method for assisting diagnosis of Alzheimer's disease (AD), and a detection reagent, a diagnosis kit and a diagnosis system for use in the method. Provided is a method for assisting diagnosis of AD, comprising the steps of: measuring an amount of a urine biomarker in a urine sample derived from urine collected from a subject; and determining whether the subject suffers from AD or has a high risk of developing AD based on the amount of the urine biomarker measured, wherein the urine biomarker is at least one urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.

Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.

Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.

Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.

Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.

Abstract: The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence set fo

Abstract: The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence set

Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.

Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.

Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.

Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.

Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.

Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.

Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.

Abstract: The present invention provides a method for detecting polymorphism of the human cytochrome P4501A2 (CYP1A2) gene in which substitution at a 2064th base, substitution at a 2640th base, and/or deletion of a -1569th base in a nontranslational region of the human cytochrome P4501A2 gene are/is detected. According to the method of the invention, new types of polymorphism of the CYP1A2 gene can be detected simply and easily with high sensitivity and accuracy, and the method requires only a small amount of a DNA sample.

Abstract: The invention provides polymorphic human arylamine N-acetyltransferase (NAT) genes, more precisely a type 1 NAT gene containing the 5'-noncoding region base sequence of SEQ ID NO:1 and the coding region-containing base sequence of SEQ ID NO:2, a type 2 NAT gene containing the sequences of SEQ ID NO:3 and SEQ ID NO:4 and a type 3 NAT gene containing the sequences of SEQ ID NO:5 and SEQ ID NO:6, as well as a method of detecting these polymorphic genes and a method of diagnosing an adverse effect or effects to be caused by an amino-containing aromatic substance.